Recently, Dynavax Technologies Corp. (DVAX) announced the completion of enrollment for the first of three cohorts of patients receiving DV-601 hepatitis B (HBV) therapy in an open-label, dose-escalating early-stage study. The second cohort has been opened for enrollment. All commercial rights to this product are with Dynavax. In the study conducted in Europe, up to 30 patients are to be administered with 6 injections of DV-601 over a period of three months. The study will evaluate the safety and tolerability of DV-601. The company expects to report top-line data from this study in the second half of 2010. HBV affects more than 350 million individuals globally. It is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. Currently the global market for HBV therapeutics is estimated at over $1 billion annually and available therapies have limited efficacy. Dynavax to Buy ...

Yesterday, Dynavax Technologies Corp. (DVAX) announced that it has resumed the late-stage registration trial of its hepatitis B (HBV) vaccine Heplisav in patients with chronic kidney disease. The trial will enroll 600 patients. Heplisav will be tested against GlaxoSmithKline plc’s (GSK) Engerix-B. The company intends to begin another late-stage registration trial in adults over 40 years of age in early 2010. Dynavax expects to complete both trials within the next 2 years. Management expects the vaccine to hit the market by the end of 2012 or early 2013.   As a reminder, Heplisav was on clinical hold in the U.S since March 17, 2008 following the occurrence of the severe adverse event (SAE) of Wegener's granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the US. Wegener's granulomatosis is an uncommon disease which results in the inflammation of blood vessels. ...

Yesterday, Dynavax Technologies Corp. (DVAX) announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its late-stage hepatitis B vaccine (HBV) Heplisav which is being developed for patients suffering from chronic kidney disease. As a reminder, Heplisav was on clinical hold in the U.S since Mar 17, 2008 following the report of the severe adverse event (SAE) of Wegener's granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the U.S. Wegener's granulomatosis is an uncommon disease which results in the inflammation of blood vessels .The vaccine is being studied for both healthy adults and patients with end-stage renal disease. Consequent to the regulatory issues, the partnership with Merck & Co. Inc. (MRK) for Heplisav ended on December 19, 2008. All rights relating to the development and commercialization of Heplisav reverted to ...

DrStockPick.com Stock Report!

Monday August 31, 2009

**************************************************************

Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath’s request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.

TAEJIN Technology, Co., Ltd., a supplier of linear and switching regulators to a wide variety of consumer and mobile applications, today announced it has selected Tower Semiconductor, Ltd. (NASDAQ: TSEM), a

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Wednesday August 26, 2009

PennyOmega.com Stock Report!

**************************************************************

Progress DataDirect (www.datadirect.com), the data infrastructure division of Progress Software Corporation (NASDAQ: PRGS) and provider of premium, vendor-independent data access and integration technologies for all major data sources has announced it will be hosting a series of free workshops to help system architects, software programmers and IT professionals interested in data access and data integration best practices.

Gulfstream Aerospace recently recognized Qwest Communications (NYSE: Q) as a top-performing supplier for its design and delivery of an integrated voice and data wide area network (WAN) connecting the aerospace company’s locations in the United States and internationally.

IMS Health (NYSE:

...

DrStockPick.com Stock Report!

Wednesday August 26, 2009

**************************************************************

Progress DataDirect (www.datadirect.com), the data infrastructure division of Progress Software Corporation (NASDAQ: PRGS) and provider of premium, vendor-independent data access and integration technologies for all major data sources has announced it will be hosting a series of free workshops to help system architects, software programmers and IT professionals interested in data access and data integration best practices.

Gulfstream Aerospace recently recognized Qwest Communications (NYSE: Q) as a top-performing supplier for its design and delivery of an integrated voice and data wide area network (WAN) connecting the aerospace company’s locations in the United States and internationally.

IMS Health (NYSE: RX),

...

MultiCell Technologies, Inc., an integrated biopharmaceutical company based in Rhode Island, announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc., a non-public Maryland-based medical research products company. The focus of the research will be the development of products for working with liver stem cells in the detection and treatment of liver cancer.

Although not one of the most common types of cancer in the U.S., liver cancer is still deadly. Nationwide there were over 21,000 new cases of primary liver cancer and intrahepatic bile duct cancer in 2008 according to the National Cancer Institute. Approximately 85% of those cases were fatal. Worldwide, liver cancer is more common due to the prevalence of hepatitis infection. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C, is the most common cancer in some parts of the world.

One of the problems in dealing with the disease

...